Gastrointestinal Cancers
13 protocols meet the specified criteria.
-
A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events -
EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation -
EA2197
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial -
EAY191
Molecular Analysis for Combination Therapy Choice (ComboMATCH) -
EAY191-A3
A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancer -
EAY191-A6
A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations -
NRG-CC005
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE) -
NRG-GI008
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) -
S2012
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC) -
TIGER-PAC
Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer -
WVU010220
Phase I/II Study of Neoadjuvant FOLFIRINOX in Combination with Peri-Operative Oral Hydroxychloroquine (FHQ) in Subjects with Resectable Adenocarcinoma of the Pancreas -
WVU020220
Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma -
WVU03HSC24
Evaluating the gut microbiome from diagnosis through surveillance in colorectal cancer patients in Appalachia